Clinical Research Directory

Inclusion Criteria: * Unilateral or bilateral, primary or secondary lymphoedema of the upper or lower limb * If cancer-related lymphoedema, approval for participation in study from oncological specialist (patient participation has to be discussed during Multidisciplinary Oncological Consult); approval if: * estimated cancer-related survival is ≥3 years * oncological safety is guaranteed: for instance, time interval since radiotherapy/ chemotherapy is ≥3 months * Lymphoedema stage 1 to 2b * Objective diagnosis of lymphoedema: ≥ 5% volume difference OR ≥ 2 minor/ 1 major criteria on lymphoscintigraphy OR presence of IndoCyanineGreen (ICG) dermal backflow * Score on Lymph-ICF questionnaire at screening: ≥ 25 / 100 (= moderate level of problems in functioning related to the development of lymphoedema) * History of at least 6 months of decongestive lymphatic therapy (DLT) until minimal pitting * Age ≥ 18 years Exclusion Criteria: * Participants with history of liposuction, lymphovenous anastomosis, lymph node transfer * Pregnant participants * Severe obese participants: BMI\>35 * Estimated cancer-related survival is \<3 years and oncological safety is not guaranteed (e.g. interval since radiotherapy/ chemotherapy is \<3 months) * In case of lower limb lymphoedema: presence of chronic venous insufficiency C4, C5, C6; deep venous thrombosis; post-thrombotic syndrome * Allergy for ICG, iodine, penicillin and sulphonamides; increased activity of thyroid gland; benign tumour in thyroid; heparin use and severe renal insufficiency